Scleritis Market Report 2026

Scleritis Market Overview

• Scleritis market size has reached to $3.93 billion in 2025 • Expected to grow to $5.95 billion in 2030 at a compound annual growth rate (CAGR) of 8.6% • Growth Driver: Impact Of Rising Autoimmune Disease Prevalence On Ocular Inflammation • Market Trend: Innovative Advances In Eye Inflammation Treatments • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Scleritis Market?

Scleritis is an inflammation of the sclera, the white part of the eye. It is often associated with autoimmune diseases and can cause severe eye pain, redness, and potential vision loss if untreated. The diagnosis and treatment of scleritis are crucial to prevent long-term damage to the eye. Early intervention helps reduce the risk of complications such as vision loss. The main types of the scleritis are anterior scleritis, posterior scleritis, and other types. Anterior scleritis refers to inflammation of the sclera's front portion, the white outer layer of the eye, leading to redness, pain, and swelling around the eyes. Treatment options comprise medications, surgery, and other treatment. It can be distributed through channels such as hospital pharmacy, retail pharmacy, online pharmacy, and other distribution channels. The condition is managed in settings such as hospitals, specialty clinics, home healthcare, and other end-users.

What Is The Scleritis Market Growth Forecast?

The scleritis market size is expected to see strong growth in the next few years. It will grow to $5.95 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to pipeline of biologic drugs for ocular inflammation, adoption of teleophthalmology platforms, development of targeted anti-inflammatory therapies, increased access to advanced imaging techniques, expansion of rare eye disease awareness programs. Major trends in the forecast period include expansion of biologic therapies for ocular inflammation, rising use of corticosteroids and immunosuppressive agents, growing adoption of combination therapy approaches, increased focus on early detection and diagnostic imaging, development of novel anti-inflammatory ophthalmic drugs.

Global Scleritis Market Segmentation

1) By Type: Anterior Scleritis, Posterior Scleritis, Other Types 2) By Treatment: Medication, Surgery, Other Treatment  3) By Distribution Channel: Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channel 4) By End-Users: Hospitals, Specialty Clinics, Home Healthcare, Other End-Users Subsegments: 1) By Anterior Scleritis: Non-Necrotizing Anterior Scleritis, Necrotizing Anterior Scleritis 2) By Posterior Scleritis: Diffuse Posterior Scleritis, Nodular Posterior Scleritis, Scleritis With Choroidal Involvement 3) By Other Types: Chronic Scleritis, Recurrent Scleritis, Infectious Scleritis

What Is The Driver Of The Scleritis Market?

The rising prevalence of autoimmune diseases is expected to drive the growth of the scleritis market going forward. Autoimmune diseases are conditions where the body's immune system mistakenly attacks its healthy cells and tissues, thinking they are foreign invaders. The rise in autoimmune diseases is linked to genetic predispositions, environmental factors, lifestyle changes, and increased awareness, leading to better diagnosis. Autoimmune diseases cause scleritis by triggering an inflammatory immune response that mistakenly attacks the scleral tissue, leading to pain and redness. For instance, in August 2024, according to the data from Public Health Scotland, a Scotland-based national organization, reported that in 2023, the Scottish Multiple Sclerosis Register (SMSR) recorded 455 newly diagnosed MS patients. Therefore, the rising prevalence of autoimmune diseases is driving the growth of the scleritis industry.

Key Players In The Global Scleritis Market

Major companies operating in the scleritis market are Pfizer Inc, Johnson And Johnson, F Hoffmann La Roche Ltd, Bayer AG, Novartis AG, Teva Pharmaceuticals USA Inc, Baxter International Inc, Boehringer Ingelheim, Regeneron Pharmaceuticals Inc, Fresenius Kabi USA LLC, Sun Pharmaceutical Industries Ltd, Perrigo Company, Horizon Therapeutics plc, Aurobindo Pharma Ltd, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Mallinckrodt Pharmaceuticals, Alvogen, Accord Healthcare, West Ward Pharmaceuticals, Jubilant Cadista Pharmaceuticals Inc, Mylan Pharmaceuticals Inc, Zydus Pharmaceuticals Inc

Global Scleritis Market Trends and Insights

Major companies operating in the scleritis market are focusing on developing advanced products, such as eye drops, to address the underlying inflammation and provide practical, non-invasive treatment options for patients. Eye drops are liquid solutions designed for direct use in the eyes to manage conditions such as irritation, dryness, inflammation, or infections. For instance, in May 2023, Entod Pharmaceuticals, an India-based pharmaceutical company, launched CYCLOTEARS eye drops in India and globally. This novel therapy for inflammatory eye disease incorporated proprietary SEDDS technology. This product enhances drug delivery and efficacy, offering a pioneering approach to address inflammation in DED. This innovation marks a significant advancement in eye inflammatory treatment, ocular myositis, and scleritis.

What Are Latest Mergers And Acquisitions In The Scleritis Market?

In January 2025, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, acquired Oxular Limited for an undisclosed amount. This acquisition provides Regeneron with an advanced delivery device for ocular gene therapies, accelerating its path to clinical readiness. Further, the company is poised to improve therapeutic precision and drive innovation in eye care by utilizing Oxular’s proprietary technologies. Oxular Limited is a UK-based biotech company specializing in developing drug and device treatments for eye disorders including scleritis.

Regional Outlook

North America was the largest region in the scleritis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Scleritis Market?

The scleritis market consists of revenues earned by entities by providing services such as ultrasound, biologic therapies, and blood tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The scleritis market includes sales of ophthalmoscopes, nonsteroidal anti-inflammatory drugs, antibiotics, eye shields or patches, and cold or warm compress kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Scleritis Market Report 2026?

The scleritis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the scleritis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.